Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000409571 | SCV000487080 | likely pathogenic | Charlevoix-Saguenay spastic ataxia | 2016-10-04 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001218622 | SCV001390510 | pathogenic | Spastic paraplegia | 2019-07-06 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant disrupts the C-terminus of the SACS protein. A different truncation (p.Arg3903*) that lies downstream of this variant has been determined to be pathogenic (PMID: 19892370, 21745802). This suggests that deletion of this region of the SACS protein is causative of disease. This variant has not been reported in the literature in individuals with SACS-related conditions. ClinVar contains an entry for this variant (Variation ID: 371485). This variant is present in population databases (rs758572409, ExAC 0.002%). This sequence change results in a premature translational stop signal in the SACS gene (p.Asn2615Ilefs*10). While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 1,965 amino acids of the SACS protein. |
Genome- |
RCV000409571 | SCV002027637 | likely pathogenic | Charlevoix-Saguenay spastic ataxia | 2021-09-05 | criteria provided, single submitter | clinical testing |